NEWS RELEASE

CRINETICS PHARMACEUTICALS TO PRESENT AT LEERINK PARTNERS ROUNDTABLE SERIES: RARE DISEASE & ONCOLOGY

2018-09-26

SAN DIEGO, Sept. 26, 2018 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that Scott Struthers, Ph.D., Founder and Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Roundtable Series: Rare Disease & Oncology in New York on Tuesday, October 2, 2018 at 11:00 a.m. ET / 8:00 a.m. PT.

A live audio webcast and replay of the fireside chat will be available for 90 days in the Investors section on the company's website at **crinetics.com**.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly, an orphan disease affecting more than 25,000 people in the United States. The company is also developing other oral nonpeptide somatostatin agonists for hyperinsulinism and neuroendocrine tumors, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. Crinetics was founded by a team of scientists with a track record of endocrine drug discovery and development.

Contact:
Marc Wilson
Chief Financial Officer
IR@crinetics.com
(858) 450-6464

Investors / Media:
Corey Davis
LifeSci Advisors
cdavis@lifesciadvisors.com
(212)-915-2577

Aline Sherwood
Scienta Communications
asherwood@scientapr.com
(312) 238-8957

Source: Crinetics Pharmaceuticals, Inc.